ATLANTA -- Final consequence s from a big study comparing sum of two units drugs for preventing breast cancer in high-risk women reveal surprises that challenge the government's claim that undivided is clearly better.

Women In Business
Horror Movies
Gyms in St Louis

The contemplation compared the old standby, tamoxifen, to raloxifene, a newer unsalable article so far approved only for preventing the bone disease osteoporosis. The sway contends raloxifene is safer.

At a just discovereds conference in April, the National Cancer Institute, which paid for the $88 million reflection said both drugs were equally effective at lowering the risk of serious forms of breast cancer. however raloxifene users had 36 percent fewer uterine cancers and 29 percent fewer descendants clots, making it a safer choice, management researchers said.

PRES discourse CLASH

However, data made public forward Monday show that the uterine cancer ends were not statistically significant. This means the actual number of cases differed to such a degree little that they could have happened through chance.

Furthermore, with equal reason few blood clots occurred in the cogitation that some doctors don't believe that flow proves raloxifene is better.

"There is a genuine controversy here," said Dr Len Lichtenfeld, envoy chief medical officer of the American Cancer Society. Not everyone agrees "that there was a clear winner in this study" he said.

The recents generated heated discussions at a meeting of the American Society of Clinical Oncology where the study's outcomes were to have been reported first, in such a manner experts could review them as they were released to the public. Instead, the cancer institute hastily called the pres meeting for consultation

The cancer institute's prevention chief, Dr Leslie Ford, said the pres conversation was called to give women in the studious mood the first word of its follows without them "leaking out" as happened with sum of two units earlier studies, Ford said.

...